EFG Capital International’s Blueprint Medicines BPMC Stock Holding History

EFG Capital International’s Portfolio BPMC Stock Details BPMC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	$348K	Buy	+5,500	New	+$299K	0.08%	124

Other funds holding BPMC

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

EFG Capital International's BPMC Position: Q2 2023 in Review

EFG Capital International opened a new position in Blueprint Medicines (BPMC) in Q2 2023: 5,500 shares worth $348K. The stake represents 0.08% of the portfolio and ranks #124 among its holdings.

221 funds tracked by Wall St. Rank hold BPMC as of Q2 2023.

EFG Capital International held 5,500 shares of Blueprint Medicines worth $348K as of Q2 2023.
Blueprint Medicines was a new EFG Capital International position in Q2 2023.
Blueprint Medicines made up 0.08% of EFG Capital International's portfolio in Q2 2023, its #124 holding.
221 funds tracked by Wall St. Rank held Blueprint Medicines as of Q2 2023.

Based on EFG Capital International's 13F filing for Q2 2023, filed 2 Aug 2023.